Phase 1 Homologous Recombination Deficiency Clinical Trials
4 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–4 of 4 trials
Recruiting
Phase 1
Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies
Advanced Malignancies With Homologous Recombination Deficiency (HRD) (Breast, Ovarian, mCRPC, Brain Metastases)
Duke Street Bio Ltd90 enrolled13 locationsNCT06458712
Recruiting
Phase 1
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
Breast CancerOvarian CancerProstate Cancer+4 more
MOMA Therapeutics220 enrolled18 locationsNCT06545942
Recruiting
Phase 1Phase 2
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
Breast CancerPancreatic CancerOvarian Cancer+3 more
AtlasMedx, Incorporated122 enrolled4 locationsNCT04503265
Recruiting
Phase 1Phase 2
EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors
Advanced Solid TumorHRR DeficiencyHomologous Recombination Deficiency
Eisbach Bio GmbH144 enrolled1 locationNCT06525298